Imperial College London

Professor Mark Gilchrist

Faculty of MedicineDepartment of Infectious Disease

Professor of Practice







Commonwealth BuildingHammersmith Campus





Mark is a Professor of practice with the National Institute of Health Research Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance. The HPRU is a partnership between Imperial College London, UK Health Security Agency, Cambridge University, Warwick University and Imperial College Health Partners. The Unit was funded, along with 14 others in priority areas from immunisation to radiation hazards, to bring Universities to work in partnership with Public Health England to support excellent health protection research relevant to the needs of Public Health England. It commenced 01 April 2020 for a 5 year period and builds on the legacy of the previous HPRU which ran from 01 April 2014 -31 March 2020. Mark is the NHS Theme lead for the prescision prescribing theme. 

Mark is a Consultant Pharmacist Infectious Diseases within Imperial College Healthcare NHS Trust and directs the Trust’s antimicrobial stewardship (AMS) programme working with colleagues across the organisation to optimise therapeutics and care. He works closely with healthcare associated / surgical site infection and hospital epidemiological departments. He directs and leads the Trust’s outpatient parenteral antimicrobial therapy (OPAT) service and is the Division of Medicine and Integrated Care Infection Prevention and Control lead.

Mark is a fellow of the Royal Pharmaceutical Society and chairs its expert antimicrobial advisory group. He was previous chair of the UK clinical pharmacy association - Pharmacy infection network.

He has delivered many lectures and workshops on AMS both at national and international level and has published around his areas of interest. He was awarded Professor of Practice from Imperial College in November 2023.



Sime FB, Wallis S, Jamieson C, et al., 2023, Evaluation of the stability of temocillin in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy in accordance with the requirements of the UK NHS Yellow Cover Document, European Journal of Hospital Pharmacy, Vol:30, ISSN:2047-9956, Pages:E76-E81

Rimmer S, Barnacle J, Gibani M, et al., 2023, The clinical presentation of monkeypox: a retrospective case-control study of patients with possible or probable monkeypox in a West London cohort, International Journal of Infectious Diseases, Vol:126, ISSN:1201-9712, Pages:48-53

Ramnarayan P, Mitting R, Whittaker E, et al., 2022, Neonatal Monkeypox Virus Infection, New England Journal of Medicine, Vol:387, ISSN:0028-4793, Pages:1618-1620

Arkell P, Wilson R, Watkins K, et al., 2022, Application of therapeutic drug monitoring to the treatment of bacterial central nervous system infection: a scoping review, Journal of Antimicrobial Chemotherapy, Vol:77, ISSN:0305-7453, Pages:3408-3413

Wilson R, Arkell P, Riezk A, et al., 2022, Addition of probenecid to oral beta-lactam antibiotics: a systematic review and meta-analysis, Journal of Antimicrobial Chemotherapy, Vol:77, ISSN:0305-7453, Pages:2364-2372

More Publications